Skip to main content

Uptake of revolutionary hepatitis drugs lowest in areas of greatest need

Broadcast 
Space to play or pause, M to mute, left and right arrows to seek, up and down arrows for volume.
Pharmacist handing bottle of pills to patient.
The group claim they can manufacture drug for around $1,400, compared to the $100,000 per course of medication, charged by pharmaceutical companies.(Thinkstock: Stockbyte)

The Northern Territory has the highest rate of hepatitis C in the country.

But research by the Doherty Institute shows it has the second lowest rate of uptake of drugs that cure the disease.

It's a similar story in Western Queensland and south Brisbane.

Some areas are doing well like the New South Wales north coast, where prevalence is high but a quarter of sufferers are getting treatment.

Experts say increasing prescription of the drugs by GPs is the key.

More Information

Featured:

Associate Professor Ben Cowie, Doherty Institute
Associate Professor Josh Davis, Menzies School of Health Research
Professor Brendan Murphy, chief medical officer, Australian Government
Helen Tyrrell, chief executive officer, Hepatitis Australia

Credits

Broadcast 
Australia, Hepatitis, Pharmaceuticals, Rural
QR code image for downloading the ABC listen app

Discover more podcasts

Download the ABC listen app to hear more of your favourite podcasts